A Phase II Dose-Response Study of Velcade and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics
- 05 Nov 2013 The extension trial has been discontinued due to low accrual and the departure of the lead investigator, according to the ClinicalTrials.gov record.
- 05 Nov 2013 The extension trial has been discontinued due to low accrual and the departure of the lead investigator, according to the ClinicalTrials.gov record.
- 19 Oct 2012 Planned end date of extension trial (NCT01062230) changed from October 2012 to December 2012, according to the ClinicalTrials.gov record.